论文部分内容阅读
目的 检测重症肝病患者凝血四项指标,分析其结果与临床意义。方法 应用美国ACL200型自动血凝仪对未经药物治疗的16例重型肝炎患者,35例肝硬化患者,42例未放、化疗肝癌患者及40例健康人进行凝血酶原时间(PT),活化部分凝血酶时间(APTT),纤维蛋白原(FIB)及凝血酶时间(TT)检测。结果 重症肝病三组PT、APTT、TT都明显延长,FIB明显减少,与健康对照组相比有显著差异(P<0.01)。结论 重症肝病患者血液处于明显低凝状态,具有出血倾向。对重症肝病患者进行有关治疗前进行凝血指标的检测,有助于早期发现肝病患者的凝血机制障碍,对其及早预防继发性出血和抢救及预后治疗有重要的临床意义。
Objective To detect four indicators of clotting in patients with severe liver disease and to analyze the results and clinical significance. Methods 16 cases of patients with severe hepatitis, 35 cases of liver cirrhosis, 42 cases of untreated and chemotherapy liver cancer and 40 healthy people without prodrugs were treated with ACL200 automatic coagulation analyzer. Prothrombin time (PT), activation Partial thrombin time (APTT), fibrinogen (FIB) and thrombin time (TT) detection. Results The levels of PT, APTT and TT in severe hepatitis were significantly prolonged and FIB was significantly decreased in the three groups (P <0.01). Conclusion The blood of patients with severe liver disease is in a state of obvious hypocoagulation with bleeding tendency. The detection of coagulation index in patients with severe liver disease before treatment is helpful to detect the clotting mechanism obstacle in the early stage of liver disease and has important clinical significance for preventing early secondary bleeding, salvage and prognosis.